ストックスクリーナーアプリを入手
5.20
1.17%
0.06
アフターアワーズ：
5.20
前日終値:
$5.14
開ける：
$5.14
24時間の取引高:
6.44M
Relative Volume:
1.19
時価総額：
$1.59B
収益：
$75.13M
当期純損益:
$-146.41M
株価収益率:
-10.60
EPS:
-0.4904
ネットキャッシュフロー:
$-174.43M
1週間 パフォーマンス:
+27.14%
1か月 パフォーマンス:
+27.45%
6か月 パフォーマンス:
+48.15%
1年 パフォーマンス:
+160.00%
1日の値動き範囲:
$5.04
$5.43
1週間の範囲:
$3.94
$5.43
52週間の値動き範囲:
$1.94
$6.515
Abcellera Biologics Inc Stock (ABCL) Company Profile
Compare ABCL vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ABCL
Abcellera Biologics Inc
|
5.20 | 1.57B | 75.13M | -146.41M | -174.43M | -0.4904 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-07 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-07-07 | 再開されました | Leerink Partners | Outperform |
| 2024-08-20 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2024-02-22 | アップグレード | The Benchmark Company | Hold → Buy |
| 2023-12-05 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2023-11-06 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2023-10-13 | 再開されました | Piper Sandler | Overweight |
| 2023-02-28 | 開始されました | Cowen | Outperform |
| 2022-12-15 | 開始されました | Goldman | Buy |
| 2022-11-16 | 開始されました | Truist | Buy |
| 2021-12-21 | 開始されました | The Benchmark Company | Buy |
| 2021-11-19 | 開始されました | Piper Sandler | Overweight |
| 2021-01-05 | 開始されました | BMO Capital Markets | Outperform |
| 2021-01-05 | 開始されました | Berenberg | Buy |
| 2021-01-05 | 開始されました | Credit Suisse | Outperform |
| 2021-01-05 | 開始されました | SVB Leerink | Outperform |
| 2021-01-05 | 開始されました | Stifel | Buy |
すべてを表示
Abcellera Biologics Inc (ABCL) 最新ニュース
Does AbCellera (ABCL) Have a Clear Path From ABCL635 Data to a Durable Business Model? - Yahoo Finance
AbCellera Biologics Inc. (ABCL) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Truist raises AbCellera stock price target on clinical data promise By Investing.com - Investing.com Nigeria
Here’s Why AbCellera (ABCL) is Among the 10 Best Penny Stocks to Buy for Long Term - Insider Monkey
Truist raises AbCellera stock price target on clinical data promise - Investing.com UK
Truist Financial Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Announces Target Price $12 - Moomoo
Wall Street Analysts Believe ABCELLERA BIOLG (ABCL) Could Rally 97.28%: Here's is How to Trade - Yahoo Finance
ABCL Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
ABCL Stock Climbs As Earnings Beat, Drug Data Fuel Bullish Outlook - StocksToTrade
10 Best Penny Stocks to Buy for Long Term - Insider Monkey
Abcellera Biologics Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Abcellera Biologics Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
AbCellera Biologics : Corporate Overview - marketscreener.com
ABCL stock clocks best week since February on clinical data anticipation, Baker Bros stake boost - MSN
AbCellera Biologics Inc.Common Shares (NQ: ABCL - FinancialContent
Director John Montalbano adds 20,000 AbCellera (ABCL) shares in open trade - Stock Titan
AbCellera Biologics Q1 earnings call highlights - MSN
Earnings Update: Here's Why Analysts Just Lifted Their AbCellera Biologics Inc. (NASDAQ:ABCL) Price Target To US$10.14 - Sahm
Jones Trading initiates coverage of AbCellera Biologics (ABCL) with buy recommendation - MSN
AbCellera Biologics Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:ABCL) 2026-05-14 - Seeking Alpha
Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year? - Yahoo Finance
AbCellera Biologics Inc. (NASDAQ:ABCL) Q1 2026 Earnings Call Transcript - Insider Monkey
AbCellera Biologics Inc. (ABCL) reports Q1 loss, beats revenue estimates - MSN
ABCL: Advancing a differentiated antibody pipeline, with ABCL635 leading and key clinical readouts ahead - TradingView
ABCL: Transitioning to a clinical-stage developer, the company advances unique antibody programs with strong potential - TradingView
AbCellera Biologics (ABCL) Q4 Revenue Surge Tests High 20.1x P/S Growth Narrative - Sahm
AbCellera Moves ABCL635 Into Phase 2 As Losses Continue - Yahoo Finance
AbCellera Biologics Bets Big on 2026 Trial Catalysts - TipRanks
Q1 2026 Abcellera Biologics Inc Earnings Call Transcript - GuruFocus
ABCL Stock Holds Support As Traders Watch Biotech Rebound - StocksToTrade
AbCellera Biologics Inc (ABCL) News, Articles, Events & Latest Updates - Stocktwits
AbCellera Biologics (ABCL) Anticipates Major Developments in 202 - GuruFocus
Stifel Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Raises Target Price to $8 - Moomoo
Cantor raises AbCellera stock price target on menopause drug data By Investing.com - Investing.com Canada
Truist Financial Maintains AbCellera Biologics(ABCL.US) With Buy Rating - 富途牛牛
Stifel raises AbCellera stock price target on trial data strength By Investing.com - Investing.com Nigeria
Stifel raises AbCellera stock price target on trial data strength - Investing.com
AbCellera Biologics Q1 2026 earnings preview - MSN
JonesTrading Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Raises Target Price to $13 - 富途牛牛
AbCellera anticipates ABCL635 Phase II topline data in Q3 as it targets at least $6B US VMS market - MSN
AbCellera Biologics Q1 2026 Earnings Call Transcript - MarketBeat
AbCellera Biologics Inc (ABCL) Q1 2026 Earnings Call Highlights: Promising Advancements Amid Financial Challenges - GuruFocus
ABCL SWOT Analysis: Key Insights from 10-Q Filing - GuruFocus
AbCellera (ABCL) Reports Strong Q1 Revenue and Progress in Clini - GuruFocus
ABCL: Q1 2026 saw robust liquidity, pipeline advances, and ABCL635 phase II progress for VMS - TradingView
Abcellera Biologics Inc (ABCL) 財務データ
収益
当期純利益
現金流量
EPS
2.98%
1.33%
大文字化:
|
ボリューム (24 時間):